Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma

BACKGROUND: Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated encouraging overall survival in uncontrolled studies in previously treated patients with advanced renal cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in renal cell carcinoma...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Motzer, Robert J., Escudier, Bernard, McDermott, David F., George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Procopio, Giuseppe, Plimack, Elizabeth R., Castellano, Daniel, Choueiri, Toni K., Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C., Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A., Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S., Xu, Li-An, Waxman, Ian M., Sharma, Padmanee
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5719487/
https://ncbi.nlm.nih.gov/pubmed/26406148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1510665
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares